1
Clinical Trials associated with Fecal Microbiota(Lifespan)Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to become a leading indication for liver transplantation in the near future. Though often associated with obesity and the metabolic syndrome, our current understanding of disease development is limited and there are few therapeutic options. Imbalance of gut bacteria is suspected to play a key role driving the progression of fatty liver disease and there is hope manipulation of these bacteria may be beneficial. This study will determine if fecal microbiota transplantation, using stool from lean donors, is an effective and safe treatment for NASH.
100 Clinical Results associated with Fecal Microbiota(Lifespan)
100 Translational Medicine associated with Fecal Microbiota(Lifespan)
100 Patents (Medical) associated with Fecal Microbiota(Lifespan)
100 Deals associated with Fecal Microbiota(Lifespan)